Female gender, n (%) | 159 (58.2) |
Age in years, median (IQR) | 85.00 (75.0–90.0) |
Estimated glomerular filtration rate in ml/min/1.73m2 (eGFR), median (IQR) | 48.0 (39.0–53.0) |
Number of other comorbidities and previous thrombotic or vascular events per patient, median (IQR) | 4.0 (3.0–5.0) |
Comorbidity or previous thrombotic/vascular event, n (%) | |
Hypertension | 244 (89.4) |
Dyslipidaemia | 168 (61.5) |
Depression/anxiety | 110 (40.3) |
Diabetes mellitus (type 1 or 2) | 109 (39.9) |
Osteoporosis | 79 (28.9) |
Obesity | 76 (27.8) |
Atrial fibrillation | 65 (23.8) |
Cardiac insufficiency/aortic aneurysm | 61 (22.3) |
Cancer | 61 (22.3) |
Previous heart attack/unstable angina/venous or pulmonary thromboembolism | 52 (19.0) |
Chronic obstructive lung disease/asthma | 46 (16.8) |
Previous ischemic stroke | 37 (13.6) |
Neurodegenerative disease/dementia | 36 (13.2) |
Chronic hepatitis B or C | 12 (4.4) |
Patients according to severity of eGFR category, n (%) | |
G3A (45–59 ml/min/1.73m2) | 162 (59.3) |
G3B (30–44 ml/min/1.73m2) | 78 (28.6) |
G4 (15–29 ml/min/1.73m2) | 28 (10.3) |
G5 (< 15 ml/min/1.73m2) | 5 (1.8) |
Dialysis, n (%) | 1 (0.4) |
Chronic kidney failure not reported as an active problem in the clinical record, n (%) | 59 (21.6) |
Number of prescribed drugs per patient, mean ± SD | 8.8 ± 3.9 |